Mohit Bansal
Stock Analyst at Wells Fargo
(4.31)
# 373
Out of 5,090 analysts
178
Total ratings
69.23%
Success rate
9.83%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Upgrades: Overweight | $90 → $125 | $99.72 | +25.35% | 12 | Nov 24, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $615 → $700 | $718.36 | -2.56% | 20 | Nov 20, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $170 → $235 | $169.70 | +38.48% | 3 | Nov 18, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | $1 → $3 | $3.48 | -13.79% | 5 | Nov 11, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Overweight | $50 → $55 | $38.50 | +42.86% | 3 | Nov 11, 2025 | |
| AMGN Amgen | Maintains: Overweight | $280 → $300 | $329.89 | -9.06% | 11 | Nov 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $140 → $145 | $121.22 | +19.62% | 12 | Oct 31, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $90 → $70 | $53.40 | +31.09% | 6 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $240 → $260 | $226.08 | +15.00% | 10 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $27 → $35 | $35.00 | - | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4 | $2.68 | +49.25% | 1 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $460 | $455.48 | +0.99% | 11 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $96.25 | +55.84% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $45.01 | +4.42% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $65 | $63.33 | +2.64% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $53 | $52.15 | +1.63% | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $970 → $1,100 | $1,010.31 | +8.88% | 17 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $140 | $181.30 | -22.78% | 14 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $18.31 | +63.84% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $44.90 | +55.90% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $26.03 | +15.25% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $155.51 | +9.32% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $19.93 | +9,307.93% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $3.10 | +1,061.29% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $10.93 | +73.83% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.14 | +5,163.16% | 4 | Dec 3, 2019 |
Merck & Co.
Nov 24, 2025
Upgrades: Overweight
Price Target: $90 → $125
Current: $99.72
Upside: +25.35%
Regeneron Pharmaceuticals
Nov 20, 2025
Maintains: Equal-Weight
Price Target: $615 → $700
Current: $718.36
Upside: -2.56%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $170 → $235
Current: $169.70
Upside: +38.48%
Ironwood Pharmaceuticals
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $1 → $3
Current: $3.48
Upside: -13.79%
Mineralys Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $38.50
Upside: +42.86%
Amgen
Nov 5, 2025
Maintains: Overweight
Price Target: $280 → $300
Current: $329.89
Upside: -9.06%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $140 → $145
Current: $121.22
Upside: +19.62%
BioMarin Pharmaceutical
Oct 28, 2025
Maintains: Overweight
Price Target: $90 → $70
Current: $53.40
Upside: +31.09%
AbbVie
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $226.08
Upside: +15.00%
Travere Therapeutics
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $35.00
Upside: -
Sep 11, 2025
Initiates: Overweight
Price Target: $4
Current: $2.68
Upside: +49.25%
Aug 6, 2025
Upgrades: Overweight
Price Target: $460
Current: $455.48
Upside: +0.99%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $96.25
Upside: +55.84%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $45.01
Upside: +4.42%
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $63.33
Upside: +2.64%
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $52.15
Upside: +1.63%
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $1,010.31
Upside: +8.88%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $181.30
Upside: -22.78%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $18.31
Upside: +63.84%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $44.90
Upside: +55.90%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $26.03
Upside: +15.25%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $155.51
Upside: +9.32%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $19.93
Upside: +9,307.93%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $3.10
Upside: +1,061.29%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $10.93
Upside: +73.83%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.14
Upside: +5,163.16%